BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innovex's Health Management Services To Deploy Nurse Educators To Support Treatment Therapies In Neurology


10/19/2005 5:12:14 PM

PARSIPPANY, N.J., Nov. 18 /PRNewswire/ -- Innovex, a commercialization unit of Quintiles Transnational, today announced an agreement with a leading biopharmaceutical manufacturer to deploy a team of nurse educators in the United States to provide support for care givers treating patients living with a major neurological disease.

Innovex provides nurse and other clinical educators as a part of Health Management Services (HMS), a service offering that helps healthcare practitioners and their staff improve patient outcomes for disease states by providing information that facilitates diagnosis, improves treatment regimens and enhances patient compliance.

"One of the most valuable contributions that HMS clinical educators make in a healthcare setting is enhancing a patient's understanding of their disease and the therapies that will benefit them," said Stewart Rosen, M.D. and Vice President, Medical Affairs, Innovex. "As with all our HMS teams, this group is demonstrating ways to enhance patient compliance that should result in improved therapeutic outcomes and quality of life for patients. Due to their extensive training, education and therapeutic expertise in this neurological therapeutic area, these clinical educators are highly regarded by the healthcare providers with whom they work."

Pete Megronigle, Vice President, Innovex Health Management Services, said: "With the deployment of this team of nurse educators, HMS has now successfully delivered 25 teams in the United States. All told, we have deployed over 400 clinicians in support of customer-sponsored initiatives to improve the understanding, identification and treatment of a wide variety of disease states. With HMS, Innovex is redefining how our pharmaceutical and biotech customers can provide caregivers with programs that truly benefit patients."

About Innovex

Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Since 1996, Innovex has built more than 110 sales forces, and hired more than 13,500 sales representatives to help launch more than 160 products for leading pharmaceutical companies in the United States. For more information, visit http://www.innovex.com/ .

Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at http://www.quintiles.com/ .

This press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter new contracts, changes in trends in the pharmaceutical industry and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.

Quintiles Transnational Corp.

CONTACT: Tom Fuldner, Media Relations, +1-919-998-2091, ormedia.info@quintiles.com , or Greg Connors, Investor Relations,+1-919-998-2000, or invest@quintiles.com , both of Quintiles TransnationalCorp.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES